AU781460B2 - Glycosylated leptin compositions and related methods - Google Patents

Glycosylated leptin compositions and related methods Download PDF

Info

Publication number
AU781460B2
AU781460B2 AU33623/00A AU3362300A AU781460B2 AU 781460 B2 AU781460 B2 AU 781460B2 AU 33623/00 A AU33623/00 A AU 33623/00A AU 3362300 A AU3362300 A AU 3362300A AU 781460 B2 AU781460 B2 AU 781460B2
Authority
AU
Australia
Prior art keywords
leptin
glycosylated
protein
seq
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU33623/00A
Other languages
English (en)
Other versions
AU3362300A (en
Inventor
Steven G Elliott
Frances H. Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU3362300A publication Critical patent/AU3362300A/en
Application granted granted Critical
Publication of AU781460B2 publication Critical patent/AU781460B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU33623/00A 1999-02-12 2000-02-11 Glycosylated leptin compositions and related methods Ceased AU781460B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24967599A 1999-02-12 1999-02-12
US09/249675 1999-02-12
PCT/US2000/003652 WO2000047741A1 (en) 1999-02-12 2000-02-11 Glycosylated leptin compositions and related methods

Publications (2)

Publication Number Publication Date
AU3362300A AU3362300A (en) 2000-08-29
AU781460B2 true AU781460B2 (en) 2005-05-26

Family

ID=22944511

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33623/00A Ceased AU781460B2 (en) 1999-02-12 2000-02-11 Glycosylated leptin compositions and related methods

Country Status (11)

Country Link
EP (1) EP1151102B1 (ja)
JP (1) JP4841037B2 (ja)
AT (1) ATE323766T1 (ja)
AU (1) AU781460B2 (ja)
CA (1) CA2359840C (ja)
CY (1) CY1107470T1 (ja)
DE (1) DE60027409T2 (ja)
DK (1) DK1151102T3 (ja)
ES (1) ES2257287T3 (ja)
PT (1) PT1151102E (ja)
WO (1) WO2000047741A1 (ja)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
CA2459015A1 (en) * 2001-08-29 2003-03-13 The University Of Buckingham Use of leptin for infant with low birth weight for prevention of obesity
DE60237100D1 (de) * 2001-10-22 2010-09-02 Amgen Inc Verwendung von leptin zur behandlung von lipoatropr prädisposition gegenüber der behandlung
US7094579B2 (en) 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression
WO2004064750A2 (en) 2003-01-22 2004-08-05 Duke University Improved constructs for expressing lysosomal polypeptides
ATE448312T1 (de) 2003-09-26 2009-11-15 Merck Serono Sa Leitsequenzen zur verwendung bei der produktion von proteinen
EP2586456B1 (en) 2004-10-29 2016-01-20 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (FGF)
US8716220B2 (en) 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
US8642543B2 (en) 2005-09-07 2014-02-04 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
WO2008067599A1 (en) * 2006-12-04 2008-06-12 Apollo Life Sciences Limited Isolated leptin and adiponectin molecules and chimeric molecules thereof
CN101778859B (zh) 2007-06-12 2014-03-26 诺和诺德公司 改良的用于生产核苷酸糖的方法
JP2009126856A (ja) * 2007-11-28 2009-06-11 Fancl Corp 血中中性脂肪上昇抑制剤
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
BR112013007388B1 (pt) 2010-09-28 2022-01-04 Amylin Pharmaceuticals, Llc Polipeptídeo tendo domínio de ligação de albumina e leptina, seu uso no tratamento de doenças, bem como composição farmacêutica que o compreende
KR102434075B1 (ko) 2012-05-17 2022-08-19 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
CA2886393C (en) 2012-09-27 2019-02-26 The Children's Medical Center Corporation Pentacyclic triterpenes for the treatment of obesity
US20160375039A1 (en) 2013-11-26 2016-12-29 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
EP3481413A4 (en) * 2016-07-08 2020-01-08 Askgene Pharma, Inc. FUSION PROTEIN WITH LEPTIN AND METHOD FOR THE PRODUCTION AND USE THEREOF
PL3509624T3 (pl) 2016-09-12 2024-03-25 Amryt Pharmaceuticals Inc. Sposób wykrywania przeciwciał neutralizujących przeciwko leptynie

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2292382A (en) * 1994-08-17 1996-02-21 Univ Rockefeller Obesity(OB) polypeptides
WO1997026916A1 (en) * 1996-01-25 1997-07-31 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
AU1208599A (en) * 1997-10-31 1999-05-24 Eli Lilly And Company Glycosylated obesity protein analogs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
ZA946122B (en) * 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
WO1996023815A1 (en) * 1995-01-31 1996-08-08 Eli Lilly And Company Ob gene product antibodies
NZ512083A (en) * 1995-11-22 2003-02-28 Amgen Inc Methods of increasing lean tissue mass using OB protein compositions
WO1997020933A2 (en) * 1995-12-06 1997-06-12 Schering Corporation MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS
JPH09176198A (ja) * 1995-12-28 1997-07-08 Kikkoman Corp 抗肥満タンパク質モノクローナル抗体及びハイブリドーマ
EP0827750A3 (en) * 1996-08-23 2002-11-20 Eli Lilly And Company Obesity protein formulations
DE69921486T2 (de) * 1998-08-10 2006-02-02 Amgen Inc., Thousand Oaks Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2292382A (en) * 1994-08-17 1996-02-21 Univ Rockefeller Obesity(OB) polypeptides
WO1997026916A1 (en) * 1996-01-25 1997-07-31 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
AU1208599A (en) * 1997-10-31 1999-05-24 Eli Lilly And Company Glycosylated obesity protein analogs

Also Published As

Publication number Publication date
DE60027409D1 (de) 2006-05-24
WO2000047741A1 (en) 2000-08-17
EP1151102A1 (en) 2001-11-07
DE60027409T2 (de) 2007-04-12
JP2002536018A (ja) 2002-10-29
CA2359840C (en) 2012-10-23
JP4841037B2 (ja) 2011-12-21
ATE323766T1 (de) 2006-05-15
CY1107470T1 (el) 2012-12-19
DK1151102T3 (da) 2006-05-29
CA2359840A1 (en) 2000-08-17
ES2257287T3 (es) 2006-08-01
PT1151102E (pt) 2006-07-31
AU3362300A (en) 2000-08-29
EP1151102B1 (en) 2006-04-19

Similar Documents

Publication Publication Date Title
AU781460B2 (en) Glycosylated leptin compositions and related methods
AU779461B2 (en) Osteoprotegerin binding proteins and receptors
AU763769B2 (en) OB fusion protein compositions and methods
RU2279441C2 (ru) Выделенный растворимый il-20 рецептор (варианты)
US6316408B1 (en) Methods of use for osetoprotegerin binding protein receptors
JP2002534962A (ja) Ｆｃ融合タンパク質としての抗肥満症タンパク質の発現および輸送
US20040067520A1 (en) OB fusion protein compositions and methods
SK77499A3 (en) Ob fusion protein compositions and methods
NZ255922A (en) Glucagon receptor, dna constructs and host cells therefor
JP2000502569A (ja) Ｏｂタンパク質レセプター及び関連組成物と関連方法
MXPA01008123A (en) Glycosylated leptin compositions and related methods
AU2004202448B2 (en) OB Fusion Protein Compositions and Methods
AU770897B2 (en) OB fusion protein compositions and methods
MXPA99009387A (en) Osteoprotegerin binding proteins and receptors
AU1834401A (en) OB protein receptor and related compositions and methods
NZ524612A (en) OB fusion protein compositions and methods